目的 制备pH、还原双重敏感的基于聚酰胺-胺树状大分子(PAMAM)的纳米载体PSSP,用于联合携载化疗药物多柔比星(DOX)及耐药逆转剂依克立达(ELC),同时对其逆转乳腺癌多药耐药的效果进行体外评价。方法 采用红外光谱FTIR对载体进行结构表征;共聚焦显微镜考察载药纳米粒在细胞内的释药情况;流式细胞术和MTT实验分别考察联合载药纳米粒对乳腺癌多药耐药的逆转作用以及体外抗肿瘤活性。结果 成功制备联合载药PSSP/多柔比星/依克立达纳米粒,并通过细胞实验证实pH、还原双重敏感性。共聚焦定位实验表明载体进入细胞后主要集中在溶酶体,在其酸性条件下促发释药并扩散入核。罗丹明123外排实验表明,依克立达可显著增加MCF-7/ADR细胞内罗丹明123的蓄积量。并且PSSP/多柔比星/依克立达纳米粒对MCF-7/ADR细胞的细胞毒性显著大于游离药多柔比星以及PSSP/多柔比星纳米粒。结论 多柔比星和依克立达联载纳米粒逆转乳腺癌多药耐药的效果显著提高,且对肿瘤细胞的毒性增强,是一种有应用前景的抗肿瘤药物递送系统。
Abstract
OBJECTIVE To prepare a redox and pH dual sensitive nano-carrier based on PAMAM in order to co-loading chemotherapeutics doxorubicin and breast cancer multidrug resistance reversal agent elacridar, and study their in vitro reversal effect. METHODS The infrared spectrum FTIR was used to characterize the carrier. Confocal was used to investigate the intracellular triggered drug release. The reversal effect of breast cancer multidrug resistance and the in vitro anti-tumor activity of doxorubicin and elacridar co-loaded nanoparticles were investigated using flow cytometry and cell toxicity tests, respectively. RESULTS The doxorubicin and elacridar co-loaded nanoparticles (PSSP/DOX/ELC) were successfully prepared, and pH-redox dual sensitive of carrier was proved by cell experiments.And the carrier was uptaken into cells and delivery to lysosome, and drug release was triggered in the lysosome acid condition, then the released drug diffused to the nucleus. The trial of rhodamine 123 accumulation and efflux assay revealed that the accumulation of rhodamine 123 was notably increased after incubation of elacridar in MCF-7/ADR cells. The cytotoxicity of PSSP/DOX/ELC nanoparticles against MCF-7/ADR cell line was significantly stronger than that of either free doxorubicin or only doxorubicin loaded nanoparticles (PSSP/DOX). CONCLUSION The reversal effect of multidrug resistance and the cytotoxicity of cancer cells were significantly enhanced by PSSP/DOX/ELC nanoparticles. PSSP/DOX/ELC nanoparticles is a promising delivery system.
关键词
依克立达 /
多柔比星 /
pH-还原双重敏感 /
多药耐药逆转
{{custom_keyword}} /
Key words
elacridar /
doxorubicin /
pH-redox dual sensitive /
multidrug resistance reversal
{{custom_keyword}} /
中图分类号:
R944
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] WU Q, YANG Z P, NIE Y Z, et al. Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches [J]. Cancer Lett, 2014, 347(2):159-166.
[2] ALEJANDRO S. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing "generally recognized as safe" (GRAS) nanopharmaceuticals: A review [J]. Adv Drug Deliv Rev, 2013, 65(13-14):1828-1851.
[3] SILVA R, VILAS-BOAS V, HELENA C, et al. Modulation of P-glycoprotein efflux pump: Induction and activation as a therapeutic strategy [J]. Pharmacol Ther, 2015,149:1-123.
[4] TAO H, KENNETH K W T, LIN Z, et al. Reversal of P-glycoprotein (P-gp) mediated multidrug resistance in colon cancer cells by cryptotanshinone and dihydrotanshinone of salvia miltiorrhiza [J]. Phytomed Inter J Phytother Phytopharmacol, 2014, 21(11):1264-1272.
[5] ZUBEN E S, MELISSA M S, MARIANNA M, et al. The mechanism of action of multidrug-resistance-linked P-glycoprotein [J]. J Bioenerg Biomembr, 2001, 33(6):481-491.
[6] RITA N M, AMAUD B, YANN P, et al. Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes [J]. J Controlled Release, 2012, 161(1):50-61.
[7] LI Z, QIU L P, CHEN Q, et al. pH-Sensitive nanoparticles of poly(L-histidine)-poly (lactide-co-glycolide)-tocopheryl polyethylene glycol succinate for anti-tumor drug delivery [J]. Acta Biomater, 2015, 11:137-150.
[8] HONG W, CHEN D W, ZHANG X J, et al. Reversing multidrug resistance by intracellular delivery of Pluronic P85 unimers [J]. Biomaterials, 2013, 34(37): 9602-9614.
[9] LOO T W, CLARKE D M. Tariquidar inhibits P-glycoprotein drug efflux but activates ATPase activity by blocking transition to an open conformation [J]. Biochem Pharmacol, 2014, 92(4):558-566.
[10] HAN M, QING L, TANG X J, et al. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex [J]. J Controlled Release, 2012, 163(2):136-144.
[11] HYAFIL F, VERGELY C, VIGNAUD P D, et al. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative[J]. Cancer Res, 1993, 53(19):4595-4602.
[12] PAJEVA I K, STERZ K, CHRISTLIEB M, et al. Interactions of the multidrug resistance modulators tariquidar and elacridar and their analogues with P-glycoprotein [J]. Chemmedchem, 2013, 8(10):1701-1713.
[13] PLANTING A S T, SONNEVELD P, GAAST A, et al. A phaseⅠand pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors [J]. Cancer Chemother Pharmacol,2005, 55(1):91-99.
[14] KUPPUSAMY P, LI H Q, ILANGOVAN G, et al. Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels [J]. Cancer Res,2002, 62(1):307-312.
[15] PODDUTURI V P, MAGANA I B, O′NEAL D P, et al. Simulation of transport and extravasation of nanoparticles in tumors which exhibit enhanced permeability and retention effect [J]. Comput Methods Programs Biomed, 2013, 112(1):58-68.
[16] HAO A, ZHANG N, GUO X, et al. EPR Effect and its application in research and development of anticancer macromolecular drugs [J]. Chin J New Drugs(中国新药杂志),2012, 21(21):2516-2520.
[17] QI Y, SHEN J, ZHANG Z, et al. Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor [J]. Adv Drug Deliv Rev, 2013, 65(13-14): 1699-1715.
[18] HU W, CHENG L, CHENG L F, et al. Redox and pH-responsive poly (amidoamine) dendrimer-poly (ethylene glycol) conjugates with disulfide linkages for efficient intracellular drug release [J]. Colloids Surf B Biointerfaces, 2014, 123(1):254-263.
[19] QIU L P, QIAO M X, CHEN Q, et al. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin [J]. Biomaterials, 2014, 35(37):9877-9887.
[20] MA B, CHAI S, LI N, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a synthetic-aminoxy peptidomimetic [J]. Int J Pharm, 2012, 424(1-2): 33-39.
[21] MARC M, MARGOT A G, AKIKO T, et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918 [J]. Clin Cancer Res, 2001, 7(4):935-941.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家自然科学基金资助项目(81302719);江苏省自然科学基金资助项目(BK20151224)
{{custom_fund}}